Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AGTC NASDAQ:AXLA NASDAQ:INMB NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$15.18-0.5%$15.81$13.50▼$25.67$3.62B0.473.32 million shs5.56 million shsAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,782 shsINMBINmune Bio$1.90+6.1%$2.01$1.71▼$11.64$50.51M1.04372,393 shs344,914 shsVYGRVoyager Therapeutics$4.65+2.2%$4.30$2.64▼$7.44$257.93M0.95820,131 shs421,476 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+5.71%-0.91%-15.71%-3.25%AGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%INMBINmune Bio0.00%+2.70%-6.40%-29.89%-62.00%VYGRVoyager Therapeutics0.00%-6.06%+13.69%+43.52%-27.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$15.18-0.5%$15.81$13.50▼$25.67$3.62B0.473.32 million shs5.56 million shsAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,782 shsINMBINmune Bio$1.90+6.1%$2.01$1.71▼$11.64$50.51M1.04372,393 shs344,914 shsVYGRVoyager Therapeutics$4.65+2.2%$4.30$2.64▼$7.44$257.93M0.95820,131 shs421,476 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+5.71%-0.91%-15.71%-3.25%AGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%INMBINmune Bio0.00%+2.70%-6.40%-29.89%-62.00%VYGRVoyager Therapeutics0.00%-6.06%+13.69%+43.52%-27.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.00Buy$27.6782.26% UpsideAGTCApplied Genetic Technologies 0.00N/AN/AN/AAXLAAxcella Health 0.00N/AN/AN/AINMBINmune Bio 2.29Hold$18.00847.37% UpsideVYGRVoyager Therapeutics 2.71Moderate Buy$12.96178.60% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, ADMA, AXLA, INMB, and AGTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)10/24/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Buy (B-)9/27/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/15/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/7/2025VYGRVoyager TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M8.49$0.54 per share28.05$1.48 per share10.26AGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51AXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AINMBINmune Bio$10K5,050.20N/AN/A$1.45 per share1.31VYGRVoyager Therapeutics$80M3.22N/AN/A$5.49 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8617.6522.00N/A44.06%41.01%28.47%11/6/2025 (Estimated)AGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.85N/AN/AN/A-253.49%-37.65%-28.89%11/11/2025 (Estimated)Latest VYGR, ADMA, AXLA, INMB, and AGTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025VYGRVoyager Therapeutics-$0.53N/AN/AN/A$7.86 millionN/A11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A10/30/2025Q3 2025INMBINmune Bio-$0.31N/AN/AN/AN/AN/A8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025VYGRVoyager Therapeutics-$0.48-$0.57-$0.09-$0.57$9.50 million$5.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78AGTCApplied Genetic Technologies0.391.401.40AXLAAxcella HealthN/A0.800.80INMBINmune BioN/A4.204.20VYGRVoyager TherapeuticsN/A5.435.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AGTCApplied Genetic Technologies22.05%AXLAAxcella Health65.07%INMBINmune Bio12.72%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%AGTCApplied Genetic Technologies4.10%AXLAAxcella Health2.20%INMBINmune Bio21.00%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableAXLAAxcella Health112.95 million2.88 millionOptionableINMBINmune Bio1026.58 million21.00 millionOptionableVYGRVoyager Therapeutics10055.47 million51.93 millionOptionableVYGR, ADMA, AXLA, INMB, and AGTC HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Receives Sell (D) Rating from Weiss RatingsOctober 25 at 7:57 PM | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Moderate Buy" by AnalystsOctober 13, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Earns Sell (D) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVoyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?October 9, 2025 | zacks.comVoyager Therapeutics (NASDAQ:VYGR) CFO Sells $36,643.48 in StockOctober 8, 2025 | insidertrades.comVoyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen Sells 7,666 SharesOctober 7, 2025 | marketbeat.comVoyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: AnalystSeptember 16, 2025 | uk.finance.yahoo.comVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVoyager Therapeutics Extends Cash Runway to 2028August 13, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)August 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from OppenheimerAugust 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from Canaccord GenuityAugust 9, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVoyager Reports Second Quarter 2025 Financial and Operating ResultsAugust 6, 2025 | globenewswire.comVoyager 1 and 2: From Earth to Interstellar Space: The Final Frontier AwaitsJuly 21, 2025 | msn.comRead the NASA ‘Voyager Declaration’ Letter of DissentJuly 21, 2025 | nytimes.comMascarene Partners Acquires Voyager TruckingJuly 18, 2025 | finance.yahoo.comMascarene buys US waste services company Voyager TruckingJuly 18, 2025 | realassets.ipe.comRVoyager Therapeutics adds new gene therapy to Alzheimer’s programJuly 18, 2025 | bioworld.comBMascarene to acquire waste services transport firm Voyager Trucking CorporationJuly 18, 2025 | pehub.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Vertical Aerospace Could Lead the eVTOL Market by 2028By Jeffrey Neal Johnson | September 30, 2025VYGR, ADMA, AXLA, INMB, and AGTC Company DescriptionsADMA Biologics NASDAQ:ADMA$15.18 -0.07 (-0.46%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$15.14 -0.04 (-0.26%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Applied Genetic Technologies NASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Axcella Health NASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.INmune Bio NASDAQ:INMB$1.90 +0.11 (+6.15%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.88 -0.02 (-1.05%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Voyager Therapeutics NASDAQ:VYGR$4.65 +0.10 (+2.20%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.69 +0.04 (+0.86%) As of 10/24/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
